Urologic 'nuisances': How to work up and relieve men's symptoms

Geriatrics

Volumn 52, Issue 2, 1997, Pages 46-54

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER NECK STENOSIS; CANCER SCREENING; DIABETES INSIPIDUS; DIAGNOSTIC TEST; HUMAN; HYPERACTIVITY; PENIS ERECTION; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; URINARY TRACT DISEASE; URINE VOLUME;

AGE FACTORS; AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC DISEASES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; URINATION DISORDERS; URODYNAMICS;

EID: 0031428204     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549-57.
2. Benign Prostatic Hyperplasia Guidelines Panel. Benign prostatic hyperplasia: Diagnosis and treatment. Clinical practice guideline number 8. Rockville, MD: U.S. Dept. of Health and Human Services, Agency for Health Care Policy and Research Publication No. 94-0582, 1994.
3. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996; 335:304-10.
4. Carter BS, Beatty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89:3367-71.
5. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 1995; 333:1401-5.
6. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335:533-9.
7. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
8. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on transurethral resection of the prostate. N Engl J Med 1995; 332:75-9.
9. Oesterling JE. Benign prostatic hyperplasia: Medical and minimally invasive treatment options. N Engl J Med 1995; 332:99-109.
10. Knoll LD, Benson RC Jr, Bilhartz DL, Minich PJ, Furlow WL. A randomized crossover study using yohimbine and isoxsuprine versus pentoxirylline in the management of vasculogenic impotence. J Urol 1996; 155:144-6.
11. Montorsi F, Strambi LF, Guazzoni G, et al. Effect of yohimbine-trazadone on psychogenic impotence: A randomized, double-blind, placebo controlled study. Urology 1994; 44:732-6.
12. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334:873-7.
13. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270:860-4.
14. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274:1214-20.
15. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Natl Cancer Inst 1996; 88:166-73.
16. Albertsen PC. A 72-year old man with localized prostate cancer. JAMA 1995; 274:69-74.
17. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs M, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Urology 1995; 46:277-89.